Faster access than browser!
32 relations: Aflibercept, Axitinib, Bevacizumab, Cabozantinib, Cediranib, Central retinal vein occlusion, Cochrane (organisation), Diabetes mellitus, Diabetic retinopathy, Granulosa cell, Intraocular pressure, Lapatinib, Lenvatinib, Macular degeneration, Off-label use, Ovarian hyperstimulation syndrome, Pazopanib, Pegaptanib, Photodynamic therapy, Ponatinib, Ramucirumab, Ranibizumab, Regorafenib, Sorafenib, Sunitinib, Targeted therapy, Thiazolidinedione, Tyrosine kinase, Vandetanib, Vascular endothelial growth factor, VEGF receptor, Verteporfin.
Aflibercept
Aflibercept is a biopharmaceutical drug invented by Regeneron Pharmaceuticals, approved in the United States and Europe for the treatment of wet macular degeneration under the trade name Eylea, and for metastatic colorectal cancer as Zaltrap.
New!!: Anti–vascular endothelial growth factor therapy and Aflibercept · See more »
Axitinib
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer.
New!!: Anti–vascular endothelial growth factor therapy and Axitinib · See more »
Bevacizumab
Bevacizumab, sold under the trade name Avastin, is medication used to treat a number of types of cancers and a specific eye disease.
New!!: Anti–vascular endothelial growth factor therapy and Bevacizumab · See more »
Cabozantinib
Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others.
New!!: Anti–vascular endothelial growth factor therapy and Cabozantinib · See more »
Cediranib
Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
New!!: Anti–vascular endothelial growth factor therapy and Cediranib · See more »
Central retinal vein occlusion
The central retinal vein is the venous equivalent of the central retinal artery and, like that blood vessel, it can suffer from occlusion (central retinal vein occlusion, also CRVO), similar to that seen in ocular ischemic syndrome.
New!!: Anti–vascular endothelial growth factor therapy and Central retinal vein occlusion · See more »
Cochrane (organisation)
Cochrane is a non-profit, non-governmental organization formed to organize medical research findings so as to facilitate evidence-based choices about health interventions faced by health professionals, patients, and policy makers.
New!!: Anti–vascular endothelial growth factor therapy and Cochrane (organisation) · See more »
Diabetes mellitus
Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which there are high blood sugar levels over a prolonged period.
New!!: Anti–vascular endothelial growth factor therapy and Diabetes mellitus · See more »
Diabetic retinopathy
Diabetic retinopathy, also known as diabetic eye disease, is a medical condition in which damage occurs to the retina due to diabetes mellitus.
New!!: Anti–vascular endothelial growth factor therapy and Diabetic retinopathy · See more »
Granulosa cell
A granulosa cell or follicular cell is a somatic cell of the sex cord that is closely associated with the developing female gamete (called an oocyte or egg) in the ovary of mammals.
New!!: Anti–vascular endothelial growth factor therapy and Granulosa cell · See more »
Intraocular pressure
Intraocular pressure (IOP) is the fluid pressure inside the eye.
New!!: Anti–vascular endothelial growth factor therapy and Intraocular pressure · See more »
Lapatinib
Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours.
New!!: Anti–vascular endothelial growth factor therapy and Lapatinib · See more »
Lenvatinib
Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
New!!: Anti–vascular endothelial growth factor therapy and Lenvatinib · See more »
Macular degeneration
Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field.
New!!: Anti–vascular endothelial growth factor therapy and Macular degeneration · See more »
Off-label use
Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.
New!!: Anti–vascular endothelial growth factor therapy and Off-label use · See more »
Ovarian hyperstimulation syndrome
Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take fertility medication to stimulate egg growth, and in other women in very rare cases.
New!!: Anti–vascular endothelial growth factor therapy and Ovarian hyperstimulation syndrome · See more »
Pazopanib
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
New!!: Anti–vascular endothelial growth factor therapy and Pazopanib · See more »
Pegaptanib
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD).
New!!: Anti–vascular endothelial growth factor therapy and Pegaptanib · See more »
Photodynamic therapy
Photodynamic therapy (PDT), sometimes called photochemotherapy, is a form of phototherapy involving light and a photosensitizing chemical substance, used in conjunction with molecular oxygen to elicit cell death (phototoxicity).
New!!: Anti–vascular endothelial growth factor therapy and Photodynamic therapy · See more »
Ponatinib
Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).
New!!: Anti–vascular endothelial growth factor therapy and Ponatinib · See more »
Ramucirumab
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.
New!!: Anti–vascular endothelial growth factor therapy and Ramucirumab · See more »
Ranibizumab
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.
New!!: Anti–vascular endothelial growth factor therapy and Ranibizumab · See more »
Regorafenib
Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).
New!!: Anti–vascular endothelial growth factor therapy and Regorafenib · See more »
Sorafenib
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
New!!: Anti–vascular endothelial growth factor therapy and Sorafenib · See more »
Sunitinib
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
New!!: Anti–vascular endothelial growth factor therapy and Sunitinib · See more »
Targeted therapy
Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy.
New!!: Anti–vascular endothelial growth factor therapy and Targeted therapy · See more »
Thiazolidinedione
The thiazolidinediones, abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, are a class of heterocyclic compounds consisting of a five-membered C3NS ring.
New!!: Anti–vascular endothelial growth factor therapy and Thiazolidinedione · See more »
Tyrosine kinase
A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell.
New!!: Anti–vascular endothelial growth factor therapy and Tyrosine kinase · See more »
Vandetanib
Vandetanib (INN, trade name Caprelsa) is an anti-cancer drug that is used for the treatment of certain tumours of the thyroid gland.
New!!: Anti–vascular endothelial growth factor therapy and Vandetanib · See more »
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF), is a signal protein produced by cells that stimulates the formation of blood vessels.
New!!: Anti–vascular endothelial growth factor therapy and Vascular endothelial growth factor · See more »
VEGF receptor
VEGF receptors are receptors for vascular endothelial growth factor (VEGF).
New!!: Anti–vascular endothelial growth factor therapy and VEGF receptor · See more »
Verteporfin
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
New!!: Anti–vascular endothelial growth factor therapy and Verteporfin · See more »
Redirects here:
Anti vascular endothelial growth factor therapy, Anti-VEGF medication, Anti-VEGF therapy.
References
[1] https://en.wikipedia.org/wiki/Anti–vascular_endothelial_growth_factor_therapy
